Trial Profile
Intermittent Hormonal Therapy With Leuprorelin (3.75 mg SR) and Flutamide in the Treatment of Stage D2 or Tx Nx M1 ≠ M1a Metastatic Cancer of the Prostate
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Flutamide
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 26 Feb 2009 Results were presented at the 2009 Genitourinary Cancers Symposium.
- 08 Jan 2009 New trial record.